This site is intended for U.S. healthcare professionals.
CIDP in adults1
The most common ARs reported in greater than 5% of subjects during a clinical trial were headache (15%; 21 of 142), fever (14%; 20 of 142), dermatitis (10%; 14 of 142), and blood pressure increase (8%; 11 of 142).
PI in patients aged 2 years and older1
The most common ARs observed at a rate of more than 5% in patients in clinical studies were headache (22%; 11 of 51), abdominal pain (14%; 7 of 51), fever (14%; 7 of 51), nausea (10%; 5 of 51), sinusitis (8%; 4 of 51), fatigue (6%; 3 of 51), and bronchitis (6%; 3 of 51).
cITP in adults1
The most common ARs observed at a rate of more than 5% in patients in a clinical trial were headache (50%; 20 of 40), fever (23%; 9 of 40), nausea (18%; 7 of 40), vomiting (10%; 4 of 40), dizziness (10%; 4 of 40), and anemia (10%; 4 of 40).
One of 40 patients with cITP treated with PANZYGA developed aseptic meningitis on day 2 of the infusion. This patient was managed with antibiotics and supportive care with recovery.
During the CIDP study, 11 patients (8%) received premedication. The use of premedication was only allowed under certain conditions. Patients who experienced 2 consecutive infusion-related adverse events that were likely to be prevented by premedication were permitted to receive antipyretics, antihistamines, or antiemetic drugs.
Only 2 patients received premedication (3.9%) for 3 infusions (0.4%) in the PI clinical study.
No patient received premedication in the PI extension study.
Premedication was not allowed in the cITP study.
PANZYGA is available in 5 vial sizes to meet individual patient needs: 25 mL (2.5 g), 50 mL (5 g), 100 mL (10 g), 200 mL (20 g), and 300 mL (30 g). PANZYGA is supplied in single-use bottles.1
Please contact your Pfizer sales representative.
Or click here to request a representative.
Patients should be carefully monitored throughout the infusion, and the infusion rate should be adjusted if adverse drug reactions related to the rate of infusion occur. The package insert for PANZYGA recommends using an appropriate dose the patient can tolerate. Click on the links to get help with PANZYGA dosing and infusion rates for CIDP, PI, and cITP.
Yes, it is recommended that after administration the infusion line be flushed with either normal saline or 5% dextrose in water.1
The IgA content level of PANZYGA is 100 µg/mL. PANZYGA is contraindicated in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.1
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2023 Pfizer Inc. All rights reserved.